Dose escalation for stage C (T3) prostate cancer: minimal rectal toxicity observed using conformal therapy.
The treatment of stage C (T3) adenocarcinoma of the prostate using external beam radiation therapy (RT) reportedly achieves clinical local control of approximately 70-80%. A dose relationship to local control has been demonstrated in prostate cancer, although a dose-related increase in complications has also been observed. To determine the maximum dose deliverable to the prostate gland while maintaining an acceptable complication rate, a prospective dose-escalation trial using a conformational planning and dose-delivery technique was initiated for patients with stage C (T3) disease. Initial results reported here are encouraging.
Sandler
H M
HM
University of Michigan Medical Center, Department of Radiation Oncology, Ann Arbor.
Perez-Tamayo
C
C
Ten Haken
R K
RK
Lichter
A S
AS
D000368:Aged; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000517:prevention & control; D011879:Radiotherapy Dosage; D012007:Rectum / Q000528:radiation effects; D014057:Tomography, X-Ray Computed